Rocket Lab Forecast, price target & analysts
Why the stock moved Beta
Rocket Lab Target price 2026 - Analyst rating & recommendation
Rocket Lab Classifications & Recommendation
Rocket Lab Price Target
| Target Price | $122.40 |
| Price | $64.57 |
| Potential | 89.56% |
| Number of Estimates | 21 |
| 21 Analysts have issued a price target Rocket Lab 2027 . The average Rocket Lab target price is $122.40. This is 89.56% higher than the current stock price. The highest price target is $141.75 119.53% , the lowest is $64.64 0.11% . | |
| A rating was issued by 26 analysts: 21 Analysts recommend Rocket Lab to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Rocket Lab stock has an average upside potential 2027 of 89.56% . Most analysts recommend the Rocket Lab stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
24 Analysts have issued a sales forecast Rocket Lab 2026 . The average Rocket Lab sales estimate is
This results in the following potential growth metrics:
18 Analysts have issued an Rocket Lab EBITDA forecast 2026. The average Rocket Lab EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
23 Rocket Lab Analysts have issued a net profit forecast 2026. The average Rocket Lab net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
23 Analysts have issued a Rocket Lab forecast for earnings per share. The average Rocket Lab EPS is
This results in the following potential growth metrics and future valuations:
Current Rocket Lab Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Raymond James |
➜
Outperform
|
Initiated | Sep 11 2026 |
| B of A Securities |
Buy
➜
Buy
|
Unchanged | Aug 31 2026 |
| Citizens |
Market Outperform
➜
Market Outperform
|
Unchanged | Aug 11 2026 |
| Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Aug 11 2026 |
| KGI Securities |
Neutral
➜
Outperform
|
Upgrade | Jul 27 2026 |
| Piper Sandler |
➜
Neutral
|
Initiated | Jul 16 2026 |
| Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Jun 30 2026 |
| Analyst Rating | Date |
|---|---|
|
Initiated
Raymond James:
➜
Outperform
|
Sep 11 2026 |
|
Unchanged
B of A Securities:
Buy
➜
Buy
|
Aug 31 2026 |
|
Unchanged
Citizens:
Market Outperform
➜
Market Outperform
|
Aug 11 2026 |
|
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Aug 11 2026 |
|
Upgrade
KGI Securities:
Neutral
➜
Outperform
|
Jul 27 2026 |
|
Initiated
Piper Sandler:
➜
Neutral
|
Jul 16 2026 |
|
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Jun 30 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
